Further investigation and confirmation of this association in a larger cohort, particularly among rectal cancer patients, would provide valuable insights for patient follow-up and treatment selection, given the significant differences in disease prognosis between patients with KRAS mutations in exons 3 and 4, as reported in the literature. This evidence concerns the gene KRAS and rectal cancer.